Skip to main content
Erschienen in:

16.10.2021 | Topic Paper

Clinical stage II seminoma: management options

verfasst von: Muhannad Alsyouf, Siamak Daneshmand

Erschienen in: World Journal of Urology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The management of clinical stage II seminoma has evolved with a recent emphasis on minimizing long-term morbidity while achieving oncologic cure.

Methods

In this review we discuss the available management options for clinical stage II seminoma with an emphasis on the emerging role of surgery in this patient population.

Results

Historically, treatment options available to clinical stage II seminoma patients were limited to radiotherapy and chemotherapy. Survival rates with these options are excellent; however, both are associated with significant long-term morbidities including cardiovascular, pulmonary, and neurologic toxicities. Additionally, higher rates of secondary malignancies are witnessed in this young patient population, decades after successful treatment of the primary cancer. Recently, retroperitoneal lymph node dissection has been proposed as a first-line treatment option for patients with low-volume metastatic seminoma.

Conclusion

The SEMS and PRIMETEST trials are two studies examining the role of primary retroperitoneal lymph node dissection in clinical stage II seminoma, and early data show significant promise.

Literatur
  1. Domont J et al (2013) A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol 31(5):697–705View Article
  2. Stephenson A et al (2019) Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol 202(2):272–281View Article
  3. Chung PW et al (2004) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45(6):754–759 (discussion 759–760)View Article
  4. Garcia-del-Muro X et al (2008) Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish germ cell cancer group study. J Clin Oncol 26(33):5416–5421View Article
  5. Haugnes HS, Oldenburg J, Bremnes RM (2015) Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol 33(9):399–406View Article
  6. Hu B, Daneshmand S (2018) Retroperitoneal lymph node dissection as primary treatment for metastatic seminoma. Adv Urol 2018:7978958View Article
  7. Giannatempo P et al (2015) Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol 26(4):657–668View Article
  8. Zagars GK, Pollack A (2001) Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51(3):643–649View Article
  9. Chung PW et al (2003) Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 56(3):746–748View Article
  10. Classen J et al (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21(6):1101–1106View Article
  11. Hallemeier CL et al (2013) Long-term outcomes of radiotherapy for stage II testicular seminoma–the Mayo clinic experience. Urol Oncol 31(8):1832–1838View Article
  12. van Leeuwen FE et al (1993) Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol 11(3):415–424View Article
  13. Beyer J et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24(4):878–888View Article
  14. Tandstad T et al (2011) Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 29(6):719–725View Article
  15. Haugnes HS et al (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20 year follow-up study. J Clin Oncol 28(30):4649–4657View Article
  16. Brydoy M et al (2005) Paternity following treatment for testicular cancer. J Natl Cancer Inst 97(21):1580–1588View Article
  17. Pont J, Albrecht W (1997) Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 68(1):1–5View Article
  18. Travis LB et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97(18):1354–1365View Article
  19. Hellesnes R et al. (2021) Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol. https://​doi.​org/​10.​1200/​JCO.​21.​00637View ArticlePubMed
  20. Stephenson AJ et al (2007) Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 25(35):5597–5602View Article
  21. Weissbach L et al (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 37(5):582–594View Article
  22. Syan-Bhanvadia S et al (2017) Midline extraperitoneal approach to retroperitoneal lymph node dissection in testicular cancer: minimizing surgical morbidity. Eur Urol 72(5):814–820View Article
  23. Warszawski N, Schmucking M (1997) Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol 31(4):355–359View Article
  24. Mezvrishvili Z, Managadze L (2006) Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma. Int Urol Nephrol 38(3–4):615–619PubMed
  25. Hu B et al (2015) Retroperitoneal lymph node dissection as first-line treatment of node-positive seminoma. Clin Genitourin Cancer 13(4):e265–e269View Article
  26. Daneshmand S et al (2021) SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma treatment. J Clin Oncol 39(6_suppl):375–375View Article
  27. Albers P et al (2019) The PRIMETEST trial: interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment. J Clin Oncol 37(7_Suppl):507–507View Article
  28. Nicol D et al (2020) MP11-05 outcomes with minimally invasive retroperitoneal lymph node dissection (MI-RPLND) and single dose carboplatin in clinical stage 2 seminoma. J Urol 203(4):136–137View Article
Metadaten
Titel
Clinical stage II seminoma: management options
verfasst von
Muhannad Alsyouf
Siamak Daneshmand
Publikationsdatum
16.10.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 2/2022
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-021-03854-8

Neu im Fachgebiet Urologie

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

Wechsel von Zugangsroute und Biopsiesteuerung: Erfahrungen eines Zentrums

Geht der Switch zur transperinealen gezielten Prostatabiopsie auf Kosten der diagnostischen Qualität? Nein, urteilen norwegische Urologinnen und Urologen nach Durchsicht von Daten aus ihrer Einrichtung.

Warum werden Hodenprothesen so selten angeboten?

Forschende aus Großbritannien haben untersucht, wie häufig eine Hodenprothese bei krebsbedingter radikaler Orchidektomie angeboten wird. Vor allem die Gründe, warum kein Implantat zur Wahl gestellt wird, sind erstaunlich. 

Genügt die biparametrische MRT für die Prostatadiagnostik?

Die multiparametrische Magnetresonanztomografie hat einen festen Platz im Screening auf klinisch signifikante Prostatakarzinome. Ob auch ein biparametrisches Vorgehen ausreicht, ist in einer Metaanalyse untersucht worden.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.